Anti-HIV Factors: Targeting Each Step of HIV's Replication Cycle

被引:10
|
作者
Colomer-Lluch, Marta [1 ]
Gollahon, Lauren S. [1 ]
Serra-Moreno, Ruth [1 ]
机构
[1] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA
关键词
Antiviral factors; TRIM5; SAMHD-1; APOBEC3G; Mx2; BST-2; Tetherin; BCA2; HUMAN-IMMUNODEFICIENCY-VIRUS; AICARDI-GOUTIERES SYNDROME; RESTRICTION FACTOR SAMHD1; SPECIES-SPECIFIC TROPISM; ANTIVIRAL ACTIVITY; RETROVIRAL RESTRICTION; BREAST-CANCER; ANTIRETROVIRAL ACTIVITY; INDOLIZINE DERIVATIVES; INTERACTION INHIBITORS;
D O I
10.2174/1570162X14999160224094621
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Similar to other animal viruses, HIV-1 relies on the contributions of the cellular machinery to ensure efficient virus propagation. However, human cells have evolved refined mechanisms to block key steps of the virus life-cycle, thereby suppressing viral replication. These cellular proteins are generally known as restriction factors, and they provide an early antiviral defense. So far, five potent restriction factors have been shown to effectively block HIV and/or SIV replication. These are TRIM5 proteins, SAMHD-1, members of the APOBEC3 (A3) family, Mx2 and Tetherin/BST-2. Results: Here, we review the antiviral mechanisms of these and other antiviral factors, their interaction with the innate immune responses, and how their functions might be exploited to clear and prevent HIV infection. Conclusion: Since the majority of vaccine approaches against HIV have failed so far, it is imperative to start looking at alternative strategies for vaccine and therapy development. By better understanding how HIV hijacks the cellular machinery for its own benefit in completing its life-cycle, and how the virus adapts to circumvent our intrinsic immunity, we will be better equipped to design compounds that specifically interrupt virus replication and spread.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [1] INHIBITION OF HIV BY AN ANTI-HIV PROTEASE SYNTHETIC PEPTIDE BLOCKS AN EARLY STEP OF VIRAL REPLICATION
    VENAUD, S
    YAHI, N
    FEHRENTZ, JL
    GUETTARI, N
    NISATO, D
    HIRSCH, I
    CHERMANN, JC
    RESEARCH IN VIROLOGY, 1992, 143 (05): : 311 - 319
  • [2] Targeting anti-HIV drugs to the CNS
    Rao, Kavitha S.
    Ghorpade, Anuja
    Labhasetwar, Vinod
    EXPERT OPINION ON DRUG DELIVERY, 2009, 6 (08) : 771 - 784
  • [3] The next step in anti-HIV gel development
    不详
    FUTURE VIROLOGY, 2009, 4 (04) : 322 - 322
  • [4] Targeting strategies for delivery of anti-HIV drugs
    Ramana, Lakshmi Narashimhan
    Anand, Appakkudal R.
    Sethuraman, Swaminathan
    Krishnan, Uma Maheswari
    Journal of Controlled Release, 2014, 192 : 271 - 283
  • [5] Targeting strategies for delivery of anti-HIV drugs
    Krishnan, Uma Maheswari, 1600, Elsevier B.V., Netherlands (192):
  • [6] Targeting strategies for delivery of anti-HIV drugs
    Ramana, Lakshmi Narashimhan
    Anand, Appakkudal R.
    Sethuraman, Swaminathan
    Krishnan, Uma Maheswari
    JOURNAL OF CONTROLLED RELEASE, 2014, 192 : 271 - 283
  • [7] The Effect of Vitamin D on Anti-HIV microRNAs and HIV Replication in Vitro Model
    Shahmahmoodi, Shohreh
    Yousefi, Maryam
    Mollaei-Kandelous, Yaghoob
    Tabatabaie, Hamideh
    Marashi, Sayed Mahdi
    Nejati, Ahmad
    MOLECULAR GENETICS MICROBIOLOGY AND VIROLOGY, 2020, 35 (03) : 189 - 193
  • [8] The Effect of Vitamin D on Anti-HIV microRNAs and HIV Replication in Vitro Model
    Maryam Shohreh Shahmahmoodi
    Yaghoob Yousefi
    Hamideh Mollaei-Kandelous
    Sayed Mahdi Tabatabaie
    Ahmad Marashi
    Molecular Genetics, Microbiology and Virology, 2020, 35 : 189 - 193
  • [9] INHIBITION OF METHYLATION IN HIV REPLICATION - POTENTIAL USE AS NOVEL ANTI-HIV DRUGS
    JOSHI, B
    CHANG, P
    MAYERS, D
    LEE, S
    EPSTEIN, JS
    HEWLETT, IK
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S24 - S24
  • [10] α-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors
    Mackewicz, CE
    Yuan, J
    Tran, P
    Diaz, L
    Mack, E
    Selsted, ME
    Levy, JA
    AIDS, 2003, 17 (14) : F23 - F32